HealthyNCT06794021
One Week Clinical Study in Subjects With Menopausal Symptoms
A study testing Dietary Supplement with Proprietary Herbal Extract Blend and GABA in people with Healthy and Menopause, run by Olly, PBC at 1 site in United States.
Trial summary
The goal of this clinical trial is to Examine the Benefits of an Oral Product in Subjects With Menopausal Symptoms. The main questions it aims to answer are: 1. To assess the efficacy for improvement of menopausal vasomotor symptoms within 24 hours compared to placebo through Daily Diary and Mobile Application 2. Read more about this study
- Who is it for?
- Ages 40 to 65 years, women onlyHealthy volunteers can take part
- What is being tested?
- Dietary Supplement with Proprietary Herbal Extract Blend and GABA
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Jan 2025to 22 Apr 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy Females aged 40 to 65 years,
- Self-reporting menopausal symptoms (> 5 hot flushes per day) and have been present for a minimum of previous 60 days prior to baseline visit.
- Reporting a variable cycle length of > 7 days different from normal
- BMI 20-40 kg/m2
- Able to read, understand, and complete the study questionnaire and records.
- Able to understand the study procedures.
Show all 9Show fewer
- Able to comply with all study requirements.
- Written informed consent to participate in the study.
- Willingness to actively participate in the study and to come to the scheduled visits.
Who cannot join
- Pregnancy or breastfeeding.
- Immune insufficiency
- Women of childbearing potential including those still having a menstrual cycle on a regular basis who are not perimenopausal, menopausal or post-menopausal.
- History of hysterectomy
- Women on hormone replacement therapy
- Use of systemic corticosteroids or immunosuppressant drugs.
Show all 14Show fewer
- Other diseases or medications that might directly interfere in the study or put the subject's health under risk.
- Employees of the institute or the brand owner or the manufactures of the product
- Cardiovascular-, chronic liver-, thyroid or kidney diseases; a history of cancer; a disease or condition that could influence the participants' ability to follow the study protocol,
- Alcohol or drug abuse
- Use of hormonal contraceptives within the last 3 months
- Use of other menopause supplements
- BP ≥160/110 mmHg
- Oophorectomy or amenorrhea > two years. Note- Habitual medicine and supplement intake will be registered prior to inclusion in the study.
Trial locations and contacts
1 site in 1 country.
United States1 site
San Francisco Research Institute
San Francisco, California, 94127
About this study
Official title: A One Week Randomized, Double Blind, Placebo Controlled, Clinical Study to Examine the Benefits of an Oral Product in Subjects With Menopausal Symptoms Including Vasomotor Symptoms (VMS).
The goal of this clinical trial is to Examine the Benefits of an Oral Product in Subjects With Menopausal Symptoms. The main questions it aims to answer are:
- To assess the efficacy for improvement of menopausal vasomotor symptoms within 24 hours compared to placebo through Daily Diary and Mobile Application
- To assess the efficacy for improvement of menopausal vasomotor symptoms hours compared to placebo through days 2-6 Daily Diary and Mobile Application
- To assess the efficacy of the investigation product on stress/anxiety, mood swings, headaches compared to placebo through days 1-6 and with use of Daily Diary, Mobile Application and validated questionnaires (GCS, MENQOL).
- To assess the efficacy of the investigation product on mood, stress and sleep at 7 days post treatment using validated questionnaires (PSQI, PSS, POMS)
- Being tested
- Dietary Supplement with Proprietary Herbal Extract Blend and GABA, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dietary Supplement with Proprietary Herbal Extract Blend and GABADietary supplement
Eligible subjects will receive active product to take daily for seven days
PlaceboOther
Eligible subjects will receive Placebo to take daily for seven days
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Oral dietary supplement. Instructions: Take 1 capsule when having a hot flash at the onset of a hot flash (not to exceed 1 capsule/day). Only treat 1 hot flash during a 24-hour period. Receives: Other: Placebo |
| Dietary Supplement with Proprietary Herbal Extract Blend and GABA | Active comparator | Oral dietary supplement. Instructions: Take 1 capsule when having a hot flash at the onset of a hot flash (not to exceed 1 capsule/day). Only treat 1 hot flash during a 24-hour period. Receives: Dietary Supplement: Dietary Supplement with Proprietary Herbal Extract Blend and GABA |
What is being measured
The primary outcome is the main question the study is designed to answer.
Daily Diary - 24hr
To assess changes in menopausal vasomotor symptoms scores within 24 hours compared to placebo through Daily Diary.
Measured: from enrollment to the end of study at seven days
Mobile App - 24hr
To assess changes in menopausal vasomotor symptoms scores within 24 hours compared to placebo through Mobile Application.
Measured: from enrollment to the end of study at seven days
Secondary outcomes (4)
Daily Dairy - Days 1-6
To assess changes in menopausal vasomotor symptoms, stress/anxiety, mood swings, and headaches scores compared to placebo through days 1-6
Measured: from enrollment to the end of study at seven days
Mobile App - Days 1-6
To assess changes in menopausal vasomotor symptoms, stress/anxiety, mood swings, and headaches scores compared to placebo through days 1-6
Measured: from enrollment to the end of study at seven days
Green Climacteric Scale (GCS) - Days 1-6
To assess changes in stress/anxiety, mood swings, and headaches scores compared to placebo through days 1-6
Measured: from enrollment to the end of study at seven days
Menopause-Specific Quality of Life (MENQOL) - Days 1-6
To assess changes in menopausal vasomotor symptoms, stress/anxiety, mood swings, and headaches scores compared to placebo through days 1-6
Measured: from enrollment to the end of study at seven days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2025
- Study start21 Jan 2025
- Primary completion31 Jan 2025
- Study completion22 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Olly, PBC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06794021
- Sponsor's protocol ID
- UNLV20241205
- Status last verified
- Jul 2025
- First submitted
- 6 Jan 2025
- Last updated
- 15 Jul 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A One Week Randomized, Double Blind, Placebo Controlled, Clinical Study to Examine the Benefits of an Oral Product in Subjects With Menopausal Symptoms Including Vasomotor Symptoms (VMS).
- ClinicalTrials.gov ID
- NCT06794021
- Acronym / sponsor ID
- UNLV20241205
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Olly, PBCIndustry (pharma, biotech, devices)
- Study start
- 21 Jan 2025 (actual)
- Primary completion
- 31 Jan 2025 (actual)
- Study completion
- 22 Apr 2025 (actual)
- First posted
- 27 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to Examine the Benefits of an Oral Product in Subjects With Menopausal Symptoms. The main questions it aims to answer are:
- To assess the efficacy for improvement of menopausal vasomotor symptoms within 24 hours compared to placebo through Daily Diary and Mobile Application
- To assess the efficacy for improvement of menopausal vasomotor symptoms hours compared to placebo through days 2-6 Daily Diary and Mobile Application
- To assess the efficacy of the investigation product on stress/anxiety, mood swings, headaches compared to placebo through days 1-6 and with use of Daily Diary, Mobile Application and validated questionnaires (GCS, MENQOL).
- To assess the efficacy of the investigation product on mood, stress and sleep at 7 days post treatment using validated questionnaires (PSQI, PSS, POMS)
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Other: PlaceboOral dietary supplement. Instructions: Take 1 capsule when having a hot flash at the onset of a hot flash (not to exceed 1 capsule/day). Only treat 1 hot flash during a 24-hour period. |
| Dietary Supplement with Proprietary Herbal Extract Blend and GABA | Active comparator | Dietary Supplement: Dietary Supplement with Proprietary Herbal Extract Blend and GABAOral dietary supplement. Instructions: Take 1 capsule when having a hot flash at the onset of a hot flash (not to exceed 1 capsule/day). Only treat 1 hot flash during a 24-hour period. |
Who may qualify
- Ages
- 40 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Healthy Females aged 40 to 65 years,
- Self-reporting menopausal symptoms (> 5 hot flushes per day) and have been present for a minimum of previous 60 days prior to baseline visit.
- Reporting a variable cycle length of > 7 days different from normal
- BMI 20-40 kg/m2
- Able to read, understand, and complete the study questionnaire and records.
Key exclusion criteria (14 listed)
- Pregnancy or breastfeeding.
- Immune insufficiency
- Women of childbearing potential including those still having a menstrual cycle on a regular basis who are not perimenopausal, menopausal or post-menopausal.
- History of hysterectomy
- Women on hormone replacement therapy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dietary Supplement with Proprietary Herbal Extract Blend and GABAEligible subjects will receive active product to take daily for seven days | Dietary supplement | Dietary Supplement with Proprietary Herbal Extract Blend and GABA |
| PlaceboEligible subjects will receive Placebo to take daily for seven days | Other | Placebo |
Primary outcome
Daily Diary - 24hr
Time frame: from enrollment to the end of study at seven days
To assess changes in menopausal vasomotor symptoms scores within 24 hours compared to placebo through Daily Diary.
Mobile App - 24hr
Time frame: from enrollment to the end of study at seven days
To assess changes in menopausal vasomotor symptoms scores within 24 hours compared to placebo through Mobile Application.
4 secondary outcomes
Daily Dairy - Days 1-6
Time frame: from enrollment to the end of study at seven days
Mobile App - Days 1-6
Time frame: from enrollment to the end of study at seven days
Green Climacteric Scale (GCS) - Days 1-6
Time frame: from enrollment to the end of study at seven days
Menopause-Specific Quality of Life (MENQOL) - Days 1-6
Time frame: from enrollment to the end of study at seven days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jul 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy
Recruiting
Trained vs. Untrained: Lower Extremity Pressure Changes
Trained Athletes, Untrained
Not yet recruitingPhase 1
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
Healthy Participants
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
RecruitingPhase 1
A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response
Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dietary Supplement with Proprietary Herbal Extract Blend and GABA in people with Healthy and Menopause, run by Olly, PBC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Daily Diary - 24hr (time frame: from enrollment to the end of study at seven days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jul 2025.